Literature DB >> 25953778

Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.

Sylvia Villeneuve1, Gil D Rabinovici2, Brendan I Cohn-Sheehy2, Cindee Madison3, Nagehan Ayakta4, Pia M Ghosh2, Renaud La Joie3, Samia Kate Arthur-Bentil5, Jacob W Vogel3, Shawn M Marks3, Manja Lehmann4, Howard J Rosen6, Bruce Reed7, John Olichney8, Adam L Boxer6, Bruce L Miller6, Ewa Borys9, Lee-Way Jin10, Eric J Huang11, Lea T Grinberg12, Charles DeCarli8, William W Seeley12, William Jagust5.   

Abstract

Amyloid-β, a hallmark of Alzheimer's disease, begins accumulating up to two decades before the onset of dementia, and can be detected in vivo applying amyloid-β positron emission tomography tracers such as carbon-11-labelled Pittsburgh compound-B. A variety of thresholds have been applied in the literature to define Pittsburgh compound-B positron emission tomography positivity, but the ability of these thresholds to detect early amyloid-β deposition is unknown, and validation studies comparing Pittsburgh compound-B thresholds to post-mortem amyloid burden are lacking. In this study we first derived thresholds for amyloid positron emission tomography positivity using Pittsburgh compound-B positron emission tomography in 154 cognitively normal older adults with four complementary approaches: (i) reference values from a young control group aged between 20 and 30 years; (ii) a Gaussian mixture model that assigned each subject a probability of being amyloid-β-positive or amyloid-β-negative based on Pittsburgh compound-B index uptake; (iii) a k-means cluster approach that clustered subjects into amyloid-β-positive or amyloid-β-negative based on Pittsburgh compound-B uptake in different brain regions (features); and (iv) an iterative voxel-based analysis that further explored the spatial pattern of early amyloid-β positron emission tomography signal. Next, we tested the sensitivity and specificity of the derived thresholds in 50 individuals who underwent Pittsburgh compound-B positron emission tomography during life and brain autopsy (mean time positron emission tomography to autopsy 3.1 ± 1.8 years). Amyloid at autopsy was classified using Consortium to Establish a Registry for Alzheimer's Disease (CERAD) criteria, unadjusted for age. The analytic approaches yielded low thresholds (standard uptake value ratiolow = 1.21, distribution volume ratiolow = 1.08) that represent the earliest detectable Pittsburgh compound-B signal, as well as high thresholds (standard uptake value ratiohigh = 1.40, distribution volume ratiohigh = 1.20) that are more conservative in defining Pittsburgh compound-B positron emission tomography positivity. In voxel-wise contrasts, elevated Pittsburgh compound-B retention was first noted in the medial frontal cortex, then the precuneus, lateral frontal and parietal lobes, and finally the lateral temporal lobe. When compared to post-mortem amyloid burden, low proposed thresholds were more sensitive than high thresholds (sensitivities: distribution volume ratiolow 81.0%, standard uptake value ratiolow 83.3%; distribution volume ratiohigh 61.9%, standard uptake value ratiohigh 62.5%) for CERAD moderate-to-frequent neuritic plaques, with similar specificity (distribution volume ratiolow 95.8%; standard uptake value ratiolow, distribution volume ratiohigh and standard uptake value ratiohigh 100.0%). A receiver operator characteristic analysis identified optimal distribution volume ratio (1.06) and standard uptake value ratio (1.20) thresholds that were nearly identical to the a priori distribution volume ratiolow and standard uptake value ratiolow. In summary, we found that frequently applied thresholds for Pittsburgh compound-B positivity (typically at or above distribution volume ratiohigh and standard uptake value ratiohigh) are overly stringent in defining amyloid positivity. Lower thresholds in this study resulted in higher sensitivity while not compromising specificity.
© The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Alzheimer's disease; beta-amyloid; biomarkers; dementia; neurodegeneration

Mesh:

Substances:

Year:  2015        PMID: 25953778      PMCID: PMC4806716          DOI: 10.1093/brain/awv112

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  64 in total

1.  Classification of primary progressive aphasia and its variants.

Authors:  M L Gorno-Tempini; A E Hillis; S Weintraub; A Kertesz; M Mendez; S F Cappa; J M Ogar; J D Rohrer; S Black; B F Boeve; F Manes; N F Dronkers; R Vandenberghe; K Rascovsky; K Patterson; B L Miller; D S Knopman; J R Hodges; M M Mesulam; M Grossman
Journal:  Neurology       Date:  2011-02-16       Impact factor: 9.910

2.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2013-02       Impact factor: 44.182

3.  Cortical thickness mediates the effect of β-amyloid on episodic memory.

Authors:  Sylvia Villeneuve; Bruce R Reed; Miranka Wirth; Claudia M Haase; Cindee M Madison; Nagehan Ayakta; Wendy Mack; Dan Mungas; Helena C Chui; Charles DeCarli; Michael W Weiner; William J Jagust
Journal:  Neurology       Date:  2014-01-31       Impact factor: 9.910

4.  Brain β-amyloid load approaches a plateau.

Authors:  Clifford R Jack; Heather J Wiste; Timothy G Lesnick; Stephen D Weigand; David S Knopman; Prashanthi Vemuri; Vernon S Pankratz; Matthew L Senjem; Jeffrey L Gunter; Michelle M Mielke; Val J Lowe; Bradley F Boeve; Ronald C Petersen
Journal:  Neurology       Date:  2013-02-27       Impact factor: 9.910

5.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

6.  Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation.

Authors:  Lea Tenenholz Grinberg; Xuehua Wang; Chao Wang; Peter Dongmin Sohn; Panos Theofilas; Manu Sidhu; John Benjamin Arevalo; Helmut Heinsen; Eric J Huang; Howard Rosen; Bruce L Miller; Li Gan; William W Seeley
Journal:  Acta Neuropathol       Date:  2013-01-31       Impact factor: 17.088

7.  Criteria for the diagnosis of corticobasal degeneration.

Authors:  Melissa J Armstrong; Irene Litvan; Anthony E Lang; Thomas H Bak; Kailash P Bhatia; Barbara Borroni; Adam L Boxer; Dennis W Dickson; Murray Grossman; Mark Hallett; Keith A Josephs; Andrew Kertesz; Suzee E Lee; Bruce L Miller; Stephen G Reich; David E Riley; Eduardo Tolosa; Alexander I Tröster; Marie Vidailhet; William J Weiner
Journal:  Neurology       Date:  2013-01-29       Impact factor: 9.910

8.  Does a positive Pittsburgh Compound B scan in a patient with dementia equal Alzheimer disease?

Authors:  Simon Ducharme; Marie-Christine Guiot; James Nikelski; Howard Chertkow
Journal:  JAMA Neurol       Date:  2013-07       Impact factor: 18.302

9.  Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue.

Authors:  Ruiqing Ni; Per-Göran Gillberg; Assar Bergfors; Amelia Marutle; Agneta Nordberg
Journal:  Brain       Date:  2013-06-11       Impact factor: 13.501

10.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Authors:  Stephen Salloway; Reisa Sperling; Nick C Fox; Kaj Blennow; William Klunk; Murray Raskind; Marwan Sabbagh; Lawrence S Honig; Anton P Porsteinsson; Steven Ferris; Marcel Reichert; Nzeera Ketter; Bijan Nejadnik; Volkmar Guenzler; Maja Miloslavsky; Daniel Wang; Yuan Lu; Julia Lull; Iulia Cristina Tudor; Enchi Liu; Michael Grundman; Eric Yuen; Ronald Black; H Robert Brashear
Journal:  N Engl J Med       Date:  2014-01-23       Impact factor: 91.245

View more
  156 in total

Review 1.  Suspected non-Alzheimer disease pathophysiology--concept and controversy.

Authors:  Clifford R Jack; David S Knopman; Gaël Chételat; Dennis Dickson; Anne M Fagan; Giovanni B Frisoni; William Jagust; Elizabeth C Mormino; Ronald C Petersen; Reisa A Sperling; Wiesje M van der Flier; Victor L Villemagne; Pieter J Visser; Stephanie J B Vos
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

2.  Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.

Authors:  Andrei G Vlassenko; Lena McCue; Mateusz S Jasielec; Yi Su; Brian A Gordon; Chengjie Xiong; David M Holtzman; Tammie L S Benzinger; John C Morris; Anne M Fagan
Journal:  Ann Neurol       Date:  2016-07-25       Impact factor: 10.422

3.  Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories.

Authors:  Brian J Lopresti; Elizabeth M Campbell; Zheming Yu; Stewart J Anderson; Ann D Cohen; Davneet S Minhas; Beth E Snitz; Sarah K Royse; Carl R Becker; Howard J Aizenstein; Chester A Mathis; Oscar L Lopez; William E Klunk; Dana L Tudorascu
Journal:  Neurobiol Aging       Date:  2020-05-31       Impact factor: 4.673

Review 4.  Future Directions in Imaging Neurodegeneration.

Authors:  Joseph C Masdeu
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

5.  The Influence of Dopamine on Cognitive Flexibility Is Mediated by Functional Connectivity in Young but Not Older Adults.

Authors:  Anne S Berry; Vyoma D Shah; William J Jagust
Journal:  J Cogn Neurosci       Date:  2018-05-23       Impact factor: 3.225

6.  Amyloid-β Positivity Predicts Cognitive Decline but Cognition Predicts Progression to Amyloid-β Positivity.

Authors:  Jeremy A Elman; Matthew S Panizzon; Daniel E Gustavson; Carol E Franz; Mark E Sanderson-Cimino; Michael J Lyons; William S Kremen
Journal:  Biol Psychiatry       Date:  2020-01-07       Impact factor: 13.382

7.  Defining imaging biomarker cut points for brain aging and Alzheimer's disease.

Authors:  Clifford R Jack; Heather J Wiste; Stephen D Weigand; Terry M Therneau; Val J Lowe; David S Knopman; Jeffrey L Gunter; Matthew L Senjem; David T Jones; Kejal Kantarci; Mary M Machulda; Michelle M Mielke; Rosebud O Roberts; Prashanthi Vemuri; Denise A Reyes; Ronald C Petersen
Journal:  Alzheimers Dement       Date:  2016-09-30       Impact factor: 21.566

8.  Regional Tau Effects on Prospective Cognitive Change in Cognitively Normal Older Adults.

Authors:  Xi Chen; Kaitlin E Cassady; Jenna N Adams; Theresa M Harrison; Suzanne L Baker; William J Jagust
Journal:  J Neurosci       Date:  2020-11-20       Impact factor: 6.167

9.  Optimizing Effect Sizes With Imaging Enrichment and Outcome Choices for Mild Alzheimer Disease Clinical Trials.

Authors:  Timothy S Chang; Edmond Teng; David Elashoff; Joshua D Grill
Journal:  Alzheimer Dis Assoc Disord       Date:  2017 Jan-Mar       Impact factor: 2.703

Review 10.  Is amyloid-β harmful to the brain? Insights from human imaging studies.

Authors:  William Jagust
Journal:  Brain       Date:  2015-11-27       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.